Advertisement
Advertisement
PGEN
Precigen, Inc. Common Stock
6.50
USDSponsored
-0.34
-5.04%
Aug 13, 15:48 UTC -4
Open
PGEN Earnings Reports
Positive Surprise Ratio
PGEN beat 14 of 43 last estimates.
33%
Next Report
Date of Next Report
Nov 11, 2026
Estimate for Q3 26 (Revenue/ EPS)
$70.59M
/$0.06
Implied change from Q2 26 (Revenue/ EPS)
+28.41%
/+20.00%
Implied change from Q3 25 (Revenue/ EPS)
+2315.97%
/-105.66%
Precigen, Inc. Common Stock earnings per share and revenue
On Aug 04, 2026, PGEN reported earnings of 0.05 USD per share (EPS) for Q2 26, beating the estimate of -0.01 USD, resulting in a 467.65% surprise. Revenue reached 54.98 million, compared to an expected 28.39 million, with a 93.65% difference. The market reacted with a +5.51% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of 0.06 USD, with revenue projected to reach 70.59 million USD, implying an increase of 20.00% EPS, and increase of 28.41% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.89
Actual
-$0.77
Surprise
+13.99%
CorMedix Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
$0.24
Actual
$0.28
Surprise
+19.44%
Cabaletta Bio, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.34
Surprise
+10.69%
Abeona Therapeutics Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.23
Actual
-$0.35
Surprise
-49.19%
Fate Therapeutics, Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.25
Surprise
+8.49%
ADC Therapeutics SA
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.21
Actual
-$0.11
Surprise
+49.12%
Pelthos Therapeutics Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$3.10
Actual
-$6.62
Surprise
-112.99%
MiNK Therapeutics, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.61
Actual
-$0.62
Surprise
-1.31%
PDS Biotechnology Corporation Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.18
Surprise
-35.75%
Biofrontera Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.05
Surprise
+53.31%
FAQ
What were Precigen, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Precigen, Inc. Common Stock reported EPS of $0.05, beating estimates by 467.65%, and revenue of $54.98M, 93.65% above expectations.
How did the market react to Precigen, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 5.51%, changed from $6.53 before the earnings release to $6.89 the day after.
When is Precigen, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 11, 2026.
What are the forecasts for Precigen, Inc. Common Stock's next earnings report?
Based on --
analysts, Precigen, Inc. Common Stock is expected to report EPS of $0.06 and revenue of $70.59M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement